|Day Low/High||85.85 / 86.63|
|52 Wk Low/High||74.97 / 96.31|
It finally did it. The Dow Jones Industrial Average smashed through 20,000 after hemming and hawing over the milestone.
After slaying its 20,000 milestone Wednesday morning, the Dow Jones Industrial Average extends gains through the afternoon to make a play for 20,100.
The Dow Jones Industrial Average finally pushes past the 20,000 milestone after teetering close to that level weeks earlier.
A series of positive earnings on Wednesday morning set the Dow Jones Industrial Average up to close in on its 20,000 milestone.
Reports from DuPont and Alibaba looked promising for the markets on Wednesday.
U.S. stock futures rise Wednesday and European stocks book solid gains as corporate earnings in the U.S. drive Wall Street higher.
News of Intesa's potential takeover bid extended Generali's three-day gains to 15%.
European stocks notched solid gains Wednesday as global equity investors build on a strong U.S. corporate earnings season, European deal speculation and encouraging economic data from Japan.
Novartis missed analysts expectations with its fourth quarter earnings but launched a $5 billion share buyback program and said it may sell its Alcon eye care unit.
The weak companies could be clobbered.
Regulators say company squelched competing drug for infant seizures.
Drugmaker faced antitrust charges over 2013 Synacthen purchase.
The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.
European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.
A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.
Ariad's primary drugs are leukemia treatment Iclusig and Brigatinib, an investigational drug product targeting non-small cell lung cancer.
As part of the agreement, Ionis and Akcea are eligible to receive $225 million in near-term payments.
One of the announcements include the hiring of former Novartis executive Christi Shaw to lead the biomedicines business starting April 3.
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
The health care sector has been a miserable performer lately -- but these five health trades are bucking the trend.
Jim Cramer says he's still 'a believer' in KKR and Opko.
Stocks kept rallying right through and after this rate hike, says Jim Cramer.
There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.
Hundreds of millions of people worldwide suffer from chronic respiratory disease. Here's how investors can profit from the companies making strides in treating COPD.
Fovista combined with the currently approved drug Lucentis failed to improve the vision of patients with wet, age-related macular degeneration compared to Lucentis alone.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.